SEQUENCE LISTING

<110> Cavanagh, Heather
Sheales, Leath

<120> Compound and Method of Treatment

<130> 801948-0006

<140> US 10/576,042
<141> 2007-01-24

<150> PCT/AU04/01430
<151> 2004-10-18

<150> AU 2003905718
<151> 2003-10-17

<160> 16

<170> PatentIn version 3.3

<210> 1
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<400> 1

Ala Ile Lys Leu Val Gln Ser Pro
1 5

<210> 2
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<400> 2

Ala Ile Lys Leu Val Gln Ser Pro Asn Gly Asn Phe Ala Ala Ser
1 5 10 15

<210> 3

<211> 30
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<400> 3

Ala Ile Lys Leu Val Gln Ser Pro Asn Gly Asn Phe Ala Ala Ser Phe
1 5 10 15

Val Leu Asp Gly Thr Lys Trp Ile Phe Lys Ser Lys Tyr Tyr
20 25 30

<210> 4
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<400> 4

Ala Ile Lys Leu Val Gln Ser Pro Asp Gly Asp Phe Ala Ala Ser
1 5 10 15

<210> 5
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Xaa can be selected from Ala, Leu or Val

<400> 5

Xaa Ile Lys Leu Val Gln Ser Pro
1 5

<210> 6
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa can be selected from Leu, Ile, Pro, or Val.

<400> 6

Ala Xaa Lys Leu Val Gln Ser Pro
1 5

<210> 7
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> Xaa can be selected from Lys, Pro, Asn, Gln, or His.

<400> 7

Ala Ile Xaa Leu Val Gln Ser Pro
1 5

<210> 8
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> Xaa can be selected from Leu, Ile, or Val.

<400> 8

Ala Ile Lys Xaa Val Gln Ser Pro
1 5

<210> 9
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> Xaa can be selected from Leu, Ile, or Val.

<400> 9

Ala Ile Lys Leu Xaa Gln Ser Pro
1 5

<210> 10
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Xaa can be selected from Gln, Asn, His, or Lys.

<400> 10

Ala Ile Lys Leu Val Xaa Ser Pro
1 5

<210> 11
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Peptide may be prepared, without limitation, by chemical synthesis methodologies, by recombinant DNA technologies, or by enzymatically or chemically treating a peptide.

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> Xaa can be selected from Ser or Thr.

<400> 11

Ala Ile Lys Leu Val Gln Xaa Pro
1 5

<210> 12
<211> 24
<212> RNA
<213> Unknown

<220>
<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 12
gcuaucaaac ugguucaguc cccg 24

<210> 13
<211> 45
<212> RNA
<213> Unknown

<220>
<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 13
gcuaucaaac ugguucaguc cccgaacggu aacuucgcug cuucc 45

<210> 14

<211> 90
<212> RNA
<213> Unknown

<220>
<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 14
gcuaucaaac ugguucaguc cccgaacggu aacuucgcug cuuccuucgu ucuggacggu 60

accaaaugga ucuucaaauc caaauacuac 90

<210> 15
<211> 24
<212> RNA
<213> Unknown

<220>
<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 15
gcaauuaagc ucguacaauc ucca 24

<210> 16
<211> 24
<212> DNA
<213> Unknown

<220>
<223> The nucleic acid molecules can be obtained, without limitation, from: genomic DNA, a genomic library, cDNA, a cDNA library, or constructing the sequence using synthetically derived nucleotides.

<400> 16
cgatagtttg accaagtcag gggc 24